Please login to the form below

Not currently logged in
Email:
Password:

cancer costs

This page shows the latest cancer costs news and features for those working in and with pharma, biotech and healthcare.

Gilead signs $3bn-plus gene-editing deal with Sangamo

Gilead signs $3bn-plus gene-editing deal with Sangamo

Gilead signs $3bn-plus gene-editing deal with Sangamo. Will use the platform for new cell-based cancer therapies. ... and cheaper to deliver - an important consideration given the current debate over the escalating costs of cancer treatment.

Latest news

  • Roche faces Kadcyla pricing pressure in the UK Roche faces Kadcyla pricing pressure in the UK

    Roche faces Kadcyla pricing pressure in the UK. Leading breast cancer charity calls on firmto reduce the drug's cost. ... Kadcyla costs around £90, 000 per course of treatment and is set to be dropped from the Cancer Drugs Fund after NHS England decided

  • Oncology directions Oncology directions

    Many cancer patients are facing severe financial strain, even bankruptcy in some cases. ... 20% of cancer treatment costs.

  • Rise in cancer therapy costs 'unsustainable' says oncologist Rise in cancer therapy costs 'unsustainable' says oncologist

    Rise in cancer therapy costs 'unsustainable' says oncologist. Leonard Saltz made the claims in his keynote presentation at ASCO. ... The rising costs of these drugs do not reflect development costs, nor do they help drive innovation, said Saltz, who

  • Express Scripts pushes for pay-for-performance in cancer Express Scripts pushes for pay-for-performance in cancer

    The PBM has published an analysis of prescription cancer drug use and costs ahead of the start of the American Society of Clinical Oncology (ASCO) meeting later this week. ... Cancer drugs made up a third of the medication costs among patients whose

  • Cancer drug spend tops $100bn in 2014 Cancer drug spend tops $100bn in 2014

    Overall therapy treatment costs for cancer per month have also increased 30% over the past decade (when adjusted for inflation). ... The report's authors note that in the US, patient out of pocket costs associated with IV cancer drugs have “ risen

More from news
Approximately 1 fully matching, plus 25 partially matching documents found.

Latest Intelligence

  • Health on instalment Health on instalment

    For example, the ophthalmic drug Luxturna, approved last year, costs $850, 000 per dose. ... Cancer drugs Kymriah and Yescarta go for $475, 000 and $375, 000 respectively.

  • Winning the war against cancer Winning the war against cancer

    on their own, the evidence to support spending, especially where new treatments would add to already expensive cancer treatment costs.'. ... Cancer is an important disease to see [its] impact on the health system.

  • An effective commercial model for cancer care An effective commercial model for cancer care

    Documenting retrospective use of a cancer product and its outcomes in tandem with direct and indirect costs incurred for such use as documented in reimbursement claims and electronic medical records (EMRs) ... Emphasising patient-provider communication

  • The rising prevalence of diabetes in Europe The rising prevalence of diabetes in Europe

    It kills more people than breast cancer and prostate cancer put together and costs society more than all cancers combined.

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest from PMHub

  • Medicines personalised for Tom, Dick and Harry

    Are the current development costs for rare diseases and cancer any higher than those for other therapy areas or are the typically high costs of such medications more concerned with offsetting ... There is an increasingly frenetic tug of war over costs

  • Pharma and free medicines: a different perspective

    The committee found that palbociclib stalled the growth of the cancer for an extra 10 months on average. ... Breast Cancer Res Treat 2015; 154:591-608; 4. Hotte SJ, et al.

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Consulting at McCann Health

We are the strategic consultancy of McCann Health. We combine fresh and creative thinking with scientific and strategic depth...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics